VANCOUVER, B.C., Sept. 30, 2003 (PRIMEZONE) -- ProtoKinetix, Inc. (OTCBB:PKTX), formally RJV Networks, Inc., announces that it has completed the global licensing assignment agreement with BioKinetix Research, Inc. (executed in July of 2003) and has redeemed 9,325,000 common shares back to the corporate treasury. The additional result of the completion of this transaction will be the elimination of certain liabilities from the ProtoKinetix, Inc. balance sheet.
The Company will provide the marketplace with an exact number of issued and outstanding common shares upon the filing of its quarterly report following the conclusion of September 2003 quarter.
The private securities litigation reform act of 1995 provides a "safe harbor'' for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission. Specifically, investors should be cautious as ProtoKinetix, Incorporated is presently a development stage biotechnology company with limited financial resources. Existing and prospective investors should undertake a thorough due diligence process, as well as seek advice from a registered securities broker prior to making an investment in this company.